May 26th 2023
New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.
May 26th 2023
Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, asks if health care providers are ready for this post pandemic world following the declaration of the end of the global health emergency from WHO in May 2023.
Government aims to streamline Medicaid billing for students with disabilities, expand health care services in schoolsMay 24th 2023
The US Department of Education, US Department of Health and Human Services, and the Biden-Harris Administration look to increase access to school-based health services, including mental health services, amid the national crisis.
Surgeon General issues advisory regarding effects social media has on youths’ mental healthMay 24th 2023
Up to 95% of youth aged 13 to 17 years reported using a social media platform and more than a third said they use social media, “almost constantly,” according to a new advisory from the Surgeon General.
FDA approves adalimumab-adbm autoinjector pen for JIA, Crohn’s diseaseMay 22nd 2023
Patients using adalimumab-adbm for chronic inflammatory disease treatment such as juvenile idiopathic arthritis (JIA), Crohn’s disease, and others, will have an autoinjector option beginning July 1, 2023, according to Boehringer Ingelheim.
How FDA-approved B-VEC will help children with dystrophic epidermolysis bullosaMay 20th 2023
Following the FDA approval of beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older, Bernard A. Cohen, MD, discusses its safety and efficacy and how it can change the treatment landscape for DEB.
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and olderMay 19th 2023
The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's supportMay 19th 2023
The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.
Early screening can play a critical role in pediatric mental healthMay 17th 2023
Thomas R. Young, MD, discusses how important early screening is in children and adolescents with regard to mental health. He believes a reduction in stigma associated with mental health is occurring and that primary care professionals are encouraging youth to discuss what might be bothering them.
Tapinarof cream 1% demonstrates positive topline results for treating pediatric ADMay 16th 2023
The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.
FDA approves scoliosis correction system for pediatric idiopathic scoliosisMay 16th 2023
The REFLECT Scoliosis Correction System from Globus Medical is intended to correct progressive scoliosis in pediatric patients while simultaneously maintaining stability and motion as well as allowing for future modulated growth.
Glucose levels are in target range at higher percentage with hybrid closed-loop systemMay 16th 2023
A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.
Study finds link between COVID-19 vaccination and vulvar ulcersMay 16th 2023
Patients first reported systemic symptoms, such as fevers, headache, and myalgias; vulvar symptoms, which included vulvar pain and dysuria, typically developed 2 days after vaccination and peaked within 5 days.
Dehydrated infant with fast breathing and sunken anterior fontanelMay 15th 2023
A 9-month-old girl with a history of grunting and poor weight gain for a few months is evaluated in the emergency department for dehydration and respiratory distress. What’s the diagnosis?